**Table e-1** Demographics and serum concentrations of 25(OH)D3 of study subjects for gene expression

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | HCs  (*N*=15) | MS  (*N*=11) | NMOSD  (*N*=13) | *p* value |
| Age | 32.55.3 | 34.38.3 | 46.514.1 | 0.001a |
| Female, *N* (%) | 8 (53.3) | 8 (72.7) | 12 (92.3) | 0.073 |
| Disease duration, months | N/A | 22.0 (4.052.0) | 25.0 (12.096.65) | 0.469 |
| Serum 25(OH)D3, mg/dl | 17.24.8 (*N*=14) | 21.710.4 (*N*=10) | 32.216.7 | 0.010a |
| On taking 1,25(OH)2D3, *N* (%) | 0 | 3/10 (30.0) | 4 (30.8) | 0.068 |
| ARR | N/A | 0.7 (0.334.0) | 0.5 (0.11.1) | 0.369 |
| EDSS | N/A | 1.0 (0.02.5) | 3.0 (1.253.25) | 0.136 |
| Use of drugs, *N*(%) | N/A | 9 (81.8)b | 11 (84.6)c | 0.855 |

N, number; ARR, annualized relapse rate; EDSS, Expanded Disability Status Scale; HCs, healthy controls; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorder; Values are presented as either meanSD or median (IQR) unless otherwise indicated.

asignificant betweenNMOSD and HCs or MS

binterferon β-1b (n=5), interferon β-1a (n=3), and teriflunomide (n=1)

cazathioprine (n=6), mycophenolate mofetil (n=3), hydroxychloroquine (n=1), and methotrexate (n=1)